246 related articles for article (PubMed ID: 17238892)
1. Minor increase of endtidal CO2 during sevoflurane-induced malignant hyperthermia.
Bonciu M; de la Chapelle A; Delpech H; Depret T; Krivosic-Horber R; Aimé MR
Paediatr Anaesth; 2007 Feb; 17(2):180-2. PubMed ID: 17238892
[TBL] [Abstract][Full Text] [Related]
2. Repeat episodes of severe muscle rigidity in a child receiving sevoflurane.
Cohen IT; Kaplan R
Paediatr Anaesth; 2006 Oct; 16(10):1077-9. PubMed ID: 16972840
[TBL] [Abstract][Full Text] [Related]
3. Delayed onset of sevoflurane-induced juvenile malignant hyperthermia after second exposure.
Chen PL; Day YJ; Su BC; Lee PC; Chen CY
Acta Anaesthesiol Taiwan; 2007 Sep; 45(3):189-93. PubMed ID: 17972624
[TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia in a patient with Graves' disease during subtotal thyroidectomy.
Nishiyama K; Kitahara A; Natsume H; Matsushita A; Nakano K; Sasaki S; Genma R; Yamamoto Y; Nakamura H
Endocr J; 2001 Apr; 48(2):227-32. PubMed ID: 11456272
[TBL] [Abstract][Full Text] [Related]
5. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane.
Snoeck MM; Gielen MJ; Tangerman A; van Egmond J; Dirksen R
Acta Anaesthesiol Scand; 2000 Mar; 44(3):334-7. PubMed ID: 10714850
[TBL] [Abstract][Full Text] [Related]
6. [Malignant hyperthermia and sevoflurane--a case report].
Claussen D; Wuttig K; Freudenberg J; Claussen A
Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):641-4. PubMed ID: 9445566
[TBL] [Abstract][Full Text] [Related]
7. Malignant hyperthermia: current perspectives.
Felice-Johnson J; Sudds T; Bennett G
Am J Hosp Pharm; 1981 May; 38(5):646-51. PubMed ID: 7282692
[TBL] [Abstract][Full Text] [Related]
8. [Two pediatric cases of malignant hyperthermia caused by sevoflurane].
Kinouchi K; Okawa M; Fukumitsu K; Tachibana K; Kitamura S; Taniguchi A
Masui; 2001 Nov; 50(11):1232-5. PubMed ID: 11758332
[TBL] [Abstract][Full Text] [Related]
9. Masseter muscle rigidity and malignant hyperthermia susceptibility.
Rosenberg H; Fletcher JE
Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
[TBL] [Abstract][Full Text] [Related]
10. [Case of malignant hyperthermia in which treatment was carried out smoothly].
Morota T; Endo K; Furuta S; Obara S; Ohmuzo H; Kaneko T; Onuma T; Watanabe K
Masui; 2007 Jul; 56(7):826-30. PubMed ID: 17633846
[TBL] [Abstract][Full Text] [Related]
11. Sevoflurane-induced malignant hyperthermia during cardiopulmonary bypass and moderate hypothermia.
Jonassen AA; Petersen AJ; Mohr S; Andersson C; Skattum J; Kvernebo K; Paulsen OG; Stokland O; Kirkebøen KA
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1062-5. PubMed ID: 15315628
[TBL] [Abstract][Full Text] [Related]
12. [Malignant hyperthermia in Austria. III. Anesthesia in susceptible patients].
Mauritz W; Hackl W; Sporn P; Steinbereithner K
Anaesthesist; 1988 Aug; 37(8):522-8. PubMed ID: 3177878
[TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia.
Christiaens F; Gepts E; D'Haese J; Camu F
Acta Anaesthesiol Belg; 1995; 46(2):93-7. PubMed ID: 8714856
[TBL] [Abstract][Full Text] [Related]
14. [Delayed onset of malignant hyperthermia crisis during a living donor liver transplantation caused by sevoflurane].
Gillmeister I; Schummer C; Hommann M; Schummer W
Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Mar; 39(3):153-6. PubMed ID: 15042505
[TBL] [Abstract][Full Text] [Related]
15. [The early diagnosis of malignant hyperthermia--the place of end-expiratory CO2 monitoring].
Schatke H; Schneider J; Abbushi W; Schneck HJ
Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):468-70. PubMed ID: 1786308
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermia during sevoflurane anaesthesia in arthrogryposis multiplex congenita with central nervous system dysfunction.
Kanaya N; Nakayama M; Nakae Y; Kobayashi I; Tsuchida H; Namiki A
Paediatr Anaesth; 1996; 6(5):428-9. PubMed ID: 8880828
[No Abstract] [Full Text] [Related]
17. A malignant hyperthermia-like reaction in a six-month-old female with a 5q chromosomal deletion.
Greenberg M; Faierman A; Fisher B; Harris B
Can J Anaesth; 2005; 52(7):772-3. PubMed ID: 16103395
[No Abstract] [Full Text] [Related]
18. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
19. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
[TBL] [Abstract][Full Text] [Related]
20. A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia.
Schuster F; Gardill A; Metterlein T; Kranke P; Roewer N; Anetseder M
Anaesthesia; 2007 Sep; 62(9):882-7. PubMed ID: 17697213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
